Dataset Information

Diagnostic Accuracy of circRNAs in Esophageal Cancer: A Meta-Analysis.

ABSTRACT:

Purpose

Early detection of esophageal cancer is beneficial to the survival and prognosis of patients. Circular RNAs (circRNAs) have been shown to be a potential biomarker for cancer, which can be used for the diagnosis of esophageal cancer. However, the roles of circRNAs in the diagnosis of esophageal cancer has been controversial. The present study, therefore, is aimed at determining the diagnostic accuracy of circRNAs in esophageal cancer.

Methods

Relevant researches were searched from PubMed, Embase, Cochrane Library, OVID, and ISI Web of Science online databases up to March 11, 2019. The estimation of diagnostic indicators, threshold effect, and publication bias were measured by a bivariate binomial mixed model, the Spearman correlation, and Deeks' funnel plot asymmetry test, respectively.

Results

Five studies from 4 articles were included in this meta-analysis. The pooled sensitivity, specificity, overall positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), and area under the receiver operating characteristics curve (AUC) were 0.79 (95% CI: 0.69-0.87), 0.85 (95% CI: 0.68-0.94), 5.27 (95% CI: 2.46-11.32), 0.24 (95% CI: 0.16-0.36), 21.66 (95% CI: 9.33-50.30), and 0.88 (95% CI: 0.84-0.90), respectively. The Spearman correlation coefficient was 0.60 (P = 0.285). The P value of Deeks' funnel plot was 0.81.

Conclusion

The above-mentioned results suggested that circRNAs possess a relatively higher diagnostic performance in distinguishing esophageal cancer patients from healthy individuals. Therefore, they may serve as potential clinical biomarkers for esophageal cancer diagnosis.

SUBMITTER: Niu C

PROVIDER: S-EPMC6732612 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Diagnostic Accuracy of circRNAs in Esophageal Cancer: A Meta-Analysis.

Niu Chen C Zhao Lei L Guo Xudong X Shen Yi Y Shao Yi Y Liu Fen F

Disease markers 20190827

<h4>Purpose</h4>Early detection of esophageal cancer is beneficial to the survival and prognosis of patients. Circular RNAs (circRNAs) have been shown to be a potential biomarker for cancer, which can be used for the diagnosis of esophageal cancer. However, the roles of circRNAs in the diagnosis of esophageal cancer has been controversial. The present study, therefore, is aimed at determining the diagnostic accuracy of circRNAs in esophageal cancer.<h4>Methods</h4>Relevant researches were search ...[more]

PMID: 31534563

Similar Datasets

Project description:Background Circular RNAs (circRNAs) are types of endogenous noncoding RNAs produced by selective splicing that are expressed highly specifically in various organisms and tissues and have numerous clinical implications in the regulation of cancer development and progression. Since circRNA is resistant to digestion by ribonucleases and has a long half-life, there is increasing evidence that circRNA can be used as an ideal candidate biomarker for the early diagnosis and prognosis of tumors. In this study, we aimed to reveal the diagnostic and prognostic value of circRNA in human pancreatic cancer (PC). Methods A systematic search for publications from inception to 22 July 2022 was conducted on Embase, PubMed, Web of Science (WOS), and the Cochrane Library databases. Available studies that correlated circRNA expression in tissue or serum with the clinicopathological, diagnostic, and prognostic values of PC patients were enrolled. Odds ratios (ORs) and corresponding 95% confidence intervals (CIs) were used to evaluate clinical pathological characteristics. Area under the curve (AUC), sensitivity, and specificity were adopted to assess diagnostic value. Hazard ratios (HRs) were utilized to assess disease-free survival (DFS) and overall survival (OS). Results This meta-analysis enrolled 32 eligible studies, including six on diagnosis and 21 on prognosis, which accounted for 2,396 cases from 245 references. For clinical parameters, high expression of carcinogenic circRNA was significantly associated with degree of differentiation (OR = 1.85, 95% CI = 1.47–2.34), TNM stage (OR = 0.46, 95% CI = 0.35–0.62), lymph node metastasis (OR = 0.39, 95% CI = 0.32–0.48), and distant metastasis (OR = 0.26, 95% CI = 0.13–0.51). As for clinical diagnostic utility, circRNA could discriminate patients with pancreatic cancer from controls, with an AUC of 0.86 (95% CI: 0.82–0.88), a relatively high sensitivity of 84%, and a specificity of 80% in tissue. In terms of prognostic significance, carcinogenic circRNA was correlated with poor OS (HR = 2.00, 95% CI: 1.76–2.26) and DFS (HR = 1.96, 95% CI: 1.47–2.62). Conclusion In summary, this study demonstrated that circRNA may act as a significant diagnostic and prognostic biomarker for pancreatic cancer.

Project description:BackgroundMutant p53 protein overexpression has been reported to induce serum antibodies against p53. Various studies assessing the diagnostic value of serum p53 antibody in patients with esophageal cancer remain controversial. This study aims to comprehensively and quantitatively summarize the potential diagnostic value of serum p53 antibody in esophageal cancer.MethodsWe systematically searched PubMed and Embase until 31st May 2012, without language restriction. Studies were assessed for quality using QUADAS (quality assessment of studies of diagnostic accuracy). Positive likelihood ratio (PLR) and negative likelihood ratio (NLR) were pooled separately and compared with overall accuracy measures diagnostic odds ratio (DOR) and symmetric summary receiver operating characteristic (sROC). The PLR and NLR and their 95% confidence interval (CI) were calculated using a fixed effects model according to the Mantel-Haensed method and random effects model based on the work of Der Simonian and laird, respectively.ResultsFifteen studies (cases?=?1079, controls?=?2260) met the inclusion criteria for the meta-analysis. Approximately 53.33% (8/15) of the included studies were of high quality (QUADAS score?8), which were retrospective case-control studies. The summary estimates for quantitative analysis of serum p53 antibody in the diagnosis of esophageal cancer were PLR 6.95 (95% CI: 4.77-9.51), NLR 0.75 (95%CI: 0.72-0.78) and DOR 9.65 (95%CI: 7.04-13.22). However, we found significant heterogeneity between NLRs.ConclusionsThe current evidence suggests serum p53 antibody has a potential diagnostic value for esophageal cancer. However, its discrimination power is not perfect because of low sensitivity.ImpactThese results suggest that s-p53-antibody may be useful for monitoring residual tumor cells and for aiding in the selection of candidates for less invasive treatment procedures because of the high specificity of s-p53-antibody. Further studies may need to identify patterns of multiple biomarkers to further increase the power of EC detection.

Dataset Information

Diagnostic Accuracy of circRNAs in Esophageal Cancer: A Meta-Analysis.

Purpose

Methods

Results

Conclusion

Publications

Diagnostic Accuracy of circRNAs in Esophageal Cancer: A Meta-Analysis.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets